Citadel Advisors
MYOV

Citadel Advisors’s Myovant Sciences Ltd. MYOV Stock Holding History

Citadel Advisors’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,900
Closed -$429K – 16060
2022
Q4 		$429K Sell
15,900
-118,100
-88% -$3.11M ﹤0.01% 8562
2022
Q3 		$2.41M Sell
134,000
-118,800
-47% -$1.9M ﹤0.01% 5232
2022
Q2 		$3.14M Buy
252,800
+122,800
+94% +$1.36M ﹤0.01% 4676
2022
Q1 		$1.73M Buy
130,000
+30,700
+31% +$412K ﹤0.01% 6411
2021
Q4 		$1.55M Buy
99,300
+17,700
+22% +$338K ﹤0.01% 6823
2021
Q3 		$1.83M Sell
81,600
-8,700
-10% -$191K ﹤0.01% 6584
2021
Q2 		$2.06M Sell
90,300
-2,900
-3% -$61K ﹤0.01% 6557
2021
Q1 		$1.92M Sell
93,200
-6,900
-7% -$157K ﹤0.01% 6481
2020
Q4 		$2.77M Buy
100,100
+3,300
+3% +$64.2K ﹤0.01% 4714
2020
Q3 		$1.36M Sell
96,800
-6,900
-7% -$128K ﹤0.01% 5456
2020
Q2 		$2.14M Buy
103,700
+82,600
+391% +$1.12M ﹤0.01% 4455
2020
Q1 		$159K Sell
21,100
-18,100
-46% -$203K ﹤0.01% 8238
2019
Q4 		$608K Buy
+39,200
New +$395K ﹤0.01% 6489

Other funds holding MYOV

HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's MYOV Position: Q1 2023 in Review

Citadel Advisors sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 100,059 shares — an estimated $2.7M sold.

Citadel Advisors first reported a position in MYOV in Q2 2019 and held it in 15 quarters. The position peaked at $17.4M in Q3 2022. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.

  • Citadel Advisors reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 100,059 Myovant Sciences Ltd. shares in Q1 2023, an estimated $2.7M.
  • Citadel Advisors first reported a position in Myovant Sciences Ltd. in Q2 2019 and held it in 15 quarters.
  • Citadel Advisors's Myovant Sciences Ltd. position peaked at $17.4M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.